Full Press Release Details
Evotec SE unveils new strategy and provides
2025 guidance bolstered by strong Q4 2024 results
| Strong Q4 2024 revenue and EBITDA results in spite of challenging market conditions. | |
| Full year guidance met, with liquidity significantly improved |
Hamburg, Germany, 17 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:
DE0005664809; NASDAQ: EVO) today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting
the path to sustainable profitable growth, following the completion of its strategic review process.
Dr Christian Wojczewski, Chief Executive Officer of Evotec, said:
"Evotec's ambitious new direction paves the way for sustainable
profitable long-term growth. We are refocusing Evotec on its core strengths: technology and science leadership, where we deliver maximum
impact for customers and patients. By combining cutting-edge technology platforms, disruptive science, and AI-driven innovation, we are
accelerating the journey from concept to cure with our partners. We delivered on 2024 financial guidance, and I am excited about the opportunities
that lie ahead of us. Together with our talented teams, we are writing the next chapter of Evotec's success story as a drug discovery
Evotec unveils new strategy to refocus on core strengths and define
clear roadmap to sustainable profitable growth
2024 revenue and EBITDA within guidance. Priority Reset on track.
Q4: Second highest quarterly revenues ever amid challenging market environment
Strengthened partnerships in 2024 paving the way for 2025 growth
in soft market environment
Guidance for full-year 2025
CAGR: Compound annual growth rate
More detailed information and financial tables are available in the
annual report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications
Webcast/Conference Call
The Company is going to host a conference call to discuss 2024 results
as well as to provide an update on the concluded strategic review process. The conference call will be held in English.
| Date: | Thursday, 17 April 2025 | |
| Time: | 2.00 pm CEST (1.00 pm BST, 8.00 am ET) |
To join the audio webcast and to access
the presentation slides, please register via this link.
The on-demand version of the webcast
will be available on our website: www.evotec.com.
Conference call details
To join via phone, please pre-register
You will then receive a confirmation email with dedicated dial-in
details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for
participants dialing in via phone is available under this link.
Evotec is a life science company with a unique business model that
delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's
multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and
production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships
and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders.
Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well
as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for
innovative therapeutics and has to-date established a portfolio of more than 100 proprietary and co-owned R&D projects from early
discovery to clinical development. Evotec operates globally with more than 4,800 highly qualified people. The Company's sites in
Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional
Forward-looking-statements
This announcement contains forward-looking statements concerning
future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "intend," "may," "might," "plan,"
"potential," "should," "target," "would" and variations of such words and similar expressions
are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues,
Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations
and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations
will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates,
which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly
disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein
to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which
any statement is based.
For further information, please contact:
EVP Head of Global Investor Relations & ESG